このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Video Discharge Instructions for Pediatric Gastroenteritis in an Emergency Department

2020年7月7日 更新者:Gonzalo Solis Garcia、Hospital General Universitario Gregorio Marañon

Video Discharge Instructions for Pediatric Gastroenteritis in an Emergency Department: a Randomized, Controlled Trial

Video discharge instructions (VDI) have been suggested as a useful strategy to improve discharge instructions in pediatric emergency units. The goal of this study is to evaluate if the addition of VDI to usual verbal information improved the comprehension of information provided to caregivers of patients who consult for acute gastroenteritis (AGE). An open-label, parallel, randomized trial was designed, enrolling patients who consult for AGE. First, caregivers answer a written test concerning AGE characteristics and management. They are randomly allocated to a control group, which receives verbal discharge instructions, or to an intervention group, which additionally receives video discharge instructions. After discharge, caregivers are contacted by telephone and answer the same test. Main outcome measure is difference between test scores in the first and the second tests, secondary endpoints are how many caregivers score 5/5 on the second test, as well as rate of return visits and caregivers satisfaction with the information received.

調査の概要

状態

完了

詳細な説明

Video discharge instructions (VDI) have been suggested as a useful strategy to improve discharge instructions in pediatric emergency units. This study is designed to evaluate if the addition of VDI to usual verbal information improves the comprehension of the information provided to caregivers of patients who consult in pediatric emergency department for acute gastroenteritis (AGE). Secondary objectives are evaluating if video instructions improve satisfaction with the information received and decrease return visits.

The study is an open-label, parallel, randomized trial which takes place between June 2019 and June 2020 in the pediatric emergency department of a third-level Spanish hospital which receives 58000 emergencies annually. Up to 3 eligible patients are enrolled every shift when one of the main investigators is present. Simple, 1:1 randomization is performed using R software. Patients are randomly assigned to a group by opening sequentially numbered paper envelopes which contain the group in which the patient will be allocated, ensuring thus allocation concealment. Written informed consent is provided before trial enrollment.

Interventions

The trial is developed in three steps: an initial written test, an information phase and a second follow-up test after discharge. After enrollment, all patients fill-in a written test before discharge, which consists of 5 questions about AGE, 1 point per correct answer. Enrolled subjects are randomly assigned to the control or intervention group. In the first group of subjects (control group) caregivers receive, after completing the test and prior to discharge, the usual verbal information and recommendations about AGE following the guidelines of the Spanish Society of Pediatric Emergencies. In the second group (intervention group) patients are shown a short 2-minute video providing the same information about AGE, in addition to verbal instructions. In both groups, instructions are given by one of the main investigators in order to provide homogeneous and consistent information. Both sets of instructions explicitly include the information that had been previously asked in the test. All patients additionally receive a discharge report which includes instructions concerning aftercare treatment.

After discharge, all caregivers are contacted by telephone and asked the same 5 questions from the initial test. The questionnaire has to be completed by the same caregiver as in the previous test. This test also includes questions about subsequent visits to either emergency units or outpatient pediatric clinics and satisfaction with the information. The first telephonic contact is established 72 hours after discharge, and if unable to contact, repeated every 1-2 days up to a total of 5 days before excluding them and considering them as lost in follow-up.

Statistical Analysis The sample size was calculated to provide a statistical power of 80% at an alpha level of 5% to detect a two-tailed difference of 0.5 points between the two groups. It was calculated that with an estimated loss rate of 15% of patients between randomization and follow-up test, assuming a 1-point variance in test results based on previous studies, this statistical power would be reached by enrolling 75 patients in each group.

All randomized patients who complete both tests are included in the primary-end point analysis as part of the group in which they were randomized, following intention-to-treat principle. The differences in test points and satisfaction between groups are analyzed using Student's T-test, and the differences in proportions are analyzed using Chi-square test. Statistical significance is set at p<0.05. Analysis are performed using Rv3.6.1 and SPSS.25 statistical softwares.

研究の種類

介入

入学 (実際)

139

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Madrid、スペイン、28009
        • Hospital General Universitario Gregorio Marañón

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1ヶ月~16年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients who met ESPGHAN criteria for AGE: decreased stool consistency and/or increased evacuation frequency during a period <7 days, associated or not to fever or vomiting.
  • Patients accompanied by a usual caregiver.

Exclusion Criteria:

  • Patients with severe dehydration
  • Patients with chronic comorbidities needing special instructions (i.e. neurologic, respiratory or cardiologic)
  • Patients whose caregivers were not able to communicate in Spanish
  • Patients who were admitted for hospitalization.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Control group: usual verbal instructions
In this group, caregivers receive, after completing the test and prior to discharge, the usual verbal information and recommendations about AGE following the guidelines of the Spanish Society of Pediatric Emergencies. The instructions are always given by one of the main investigators to provide homogeneity in the information
実験的:Intervention group: video discharge instructions
Additionally to the verbal information, patients are shown a short 2-minute video providing the same information about AGE that would be given by verbal information.
Short video (2 minutes) including information about clinical features, management and follow up of pediatric patients with acute gastroenteritis

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in test score
時間枠:From 3 days to 10 days after first emergency care visit
We calculated the difference between the score obtained in the initial test and the score obteined in the follow-up test and compared between groups. Scores are based on a 5-question test, minimum score is 0 points and maximum score (best score) is 5 points
From 3 days to 10 days after first emergency care visit

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of caregivers getting a total score of 5 points
時間枠:From 3 days to 10 days after first emergency care visit
We measured how many caregivers got a 5-score (perfect) in the follow up test after interventions, and compared between groups
From 3 days to 10 days after first emergency care visit
Rate of return visits
時間枠:72 hours from from the first emergency care visit
We asked caregivers whether they had returned to emergency care or to pediatric outpatient clinics for the same problem after the first visit.
72 hours from from the first emergency care visit
Satisfaction score with the information received
時間枠:From 3 days to 10 days after first emergency care visit
We asked caregivers to give a score between 1 and 10 (1 very unsatisfied, 10 very satisfied) regarding how useful they felt that the information given to them had been.
From 3 days to 10 days after first emergency care visit

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Gonzalo Solís, M.D.、Hospital General Universitario Gregorio Marañón

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年6月1日

一次修了 (実際)

2020年3月31日

研究の完了 (実際)

2020年6月1日

試験登録日

最初に提出

2020年6月23日

QC基準を満たした最初の提出物

2020年7月7日

最初の投稿 (実際)

2020年7月9日

学習記録の更新

投稿された最後の更新 (実際)

2020年7月9日

QC基準を満たした最後の更新が送信されました

2020年7月7日

最終確認日

2020年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All collected IPD are available under request.

IPD 共有時間枠

Data will be available as soon as published. It will be available for 20 years (year 2040)

IPD 共有アクセス基準

Investigators with research accepted by a research ethics committee conducting research in this area.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する